It included nine studies with exenatide and liraglutide as interventions and involved a total of 286 children and showed that GLP-1 analogs reduced overall body weight by -1.86 kg and more significant weight reduction was seen in children with obesity (-2.74 kg) than in children with diabetes (-0.97 kg). The gene discussed is GLP1R; the disease is Obesity.